INSITU BIOLOGICS
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
INSITU BIOLOGICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Minnesota City, Minnesota, United States
Country:
United States
Website Url:
http://www.insitubiologics.com
Total Employee:
1+
Status:
Active
Contact:
651-337-4799
Email Addresses:
[email protected]
Total Funding:
6.97 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Google Google Cloud MediaElement.js Google Cloud Iowa Unbounce Barracuda Networks
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Current Employees Featured
Founder
Official Site Inspections
http://www.insitubiologics.com
- Host name: 33.120.215.35.bc.googleusercontent.com
- IP address: 35.215.120.33
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Insitu Biologics"
InSitu Biologics | Localized Treatment of โฆ
InSitu Biologics is an emerging biotech company focused on development of a multi-phase prolonged release drug delivery platform for localized treatment of pain, cancer, and infection.See details»
Leadership | InSitu Biologics - Non-Opioid โฆ
Bill Taylor is a co-founder and the Chief Science Officer at InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a โฆSee details»
InSitu Biologics, Inc. | LinkedIn
InSitu Biologics, Inc. Pharmaceutical Manufacturing Oakdale, Minnesota 435 followers InSitu Biologics is an emerging biotech company focusing on development of INSB200, a non-opiate โฆSee details»
Insitu Biologics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 651-337-4799 InSitu Biologics is a developer of a drug delivery platform designed to focus on โฆSee details»
InSitu Biologics Company Profile | Management and Employees โฆ
Www.insitubiologics.com InSitu Biologics Profile and History InSitu Biologics: InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release โฆSee details»
insitu_1a.htm - SEC.gov
Email: [email protected]. 2155 Woodlane Drive, Suite 102. Woodbury, MN 55125. 651-337-4799 ... We and our third-party collaborators, if relevant, may be unable to establish a sufficient sales and marketing organization on a timely โฆSee details»
InSitu Biologics - Overview, News & Similar companies - ZoomInfo
InSitu Biologics contact info: Phone number: (651) 337-4799 Website: www.insitubiologics.com What does InSitu Biologics do? InSitu Biologics: InSitu Biologics is an emerging biotech โฆSee details»
Kevin P. Bassett - InSitu Biologics
December 28, 2021 . Dear InSitu Biologics Shareholders, We recently shared a report that US overdose mortality surged to a record 93,000 fatalities in 2020.See details»
InSitu Biologics | Manhattan Street Capital
Overview. According to The New Guidelines Released for Postoperative Pain Management, by Dr. Laurie Barclay and Pauline Anderson, acute postoperative pain is common, occurring in more than 80% of patients, with approximately โฆSee details»
InSitu Biologics - Craft
InSitu Biologics is a biotech company focusing on the development of AnestaGel, a non-opiate painkiller. Its product, Matrix BioHydrogel, can be used in post-operative surgical procedures.See details»
InSitu Biologics - VentureRadar
Website: http://www.insitubiologics.com/ Develops a multi-phase prolonged release drug delivery platform for localized treatment of pain, cancer, and infection using ...See details»
InSitu Biologics, Inc. (InSitu Biologics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ โฆ
OAKDALE, Minn.--(BUSINESS WIRE)--InSitu Biologics, Inc. will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine โฆSee details»
InSitu Biologics. Inc - Facebook
Aug 22, 2023 InSitu Biologics. Inc. 654 likes. InSitu Biologics is an emerging biotech company focused on development of a multi-phase prolonged reSee details»
InSitu Biologics โ Funding, Valuation, Investors, News
Essential stats, news, real-time insights on InSitu Biologics. Connect with decision makers, founders, investors. Explore valuation, funding rounds, reviews.See details»
Non-opiate Painkiller, AnestaGel, Found Superior In Preclinical Tests
Jan 25, 2017 For more information, please contact James Segermark, CEO, at (651) 289-6444 or visit www.insitubiologics.com. InSitu Biologics, LLC makes no representations or โฆSee details»
InSitu Biologics Launches Regulation A+ Investment Opportunity โฆ
WOODBURY, Minn., July 31, 2018 /PRNewswire/ -- InSitu Biologics, LLC (www.insitubiologics.com), an emerging drug company focused on development of a โฆSee details»
CEO Update: December 2021 - InSitu Biologics
Dec 28, 2021 InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in process development work, published โฆSee details»
News & Events | InSitu Biologics - Opiod-Free Pain Management
Dec 18, 2020 Our news & events blog will let you stay tuned with our latest events, press releases, CEO updates and more.See details»
https://insitubiologics.com/insb200... - InSitu Biologics. Inc
Oct 29, 2021 https://insitubiologics.com/insb200-poster-chosen-best-of-meeting-by-asra-pain-meeting-2021/ The American Society of Regional Anesthesia has chosen InSitu Biologics ...See details»
InSitu Biologics: Over $2M in Investments Using Reg A+ Mini-IPO โฆ
WOODBURY, Minn., Dec. 4, 2018 /PRNewswire/ -- InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGelโข, has received over $2 million in โฆSee details»